JP2019500011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500011A5 JP2019500011A5 JP2018521237A JP2018521237A JP2019500011A5 JP 2019500011 A5 JP2019500011 A5 JP 2019500011A5 JP 2018521237 A JP2018521237 A JP 2018521237A JP 2018521237 A JP2018521237 A JP 2018521237A JP 2019500011 A5 JP2019500011 A5 JP 2019500011A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- immunoglobulin molecule
- heterodimeric bispecific
- bispecific immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 35
- 102000018358 immunoglobulin Human genes 0.000 claims 35
- 239000012634 fragment Substances 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 3
- 239000000833 heterodimer Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000002619 cytotoxin Substances 0.000 claims 2
- 239000000975 dye Substances 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 206010006007 bone sarcoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 230000004850 protein–protein interaction Effects 0.000 claims 1
- -1 radioisotope Substances 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15192851.2 | 2015-11-03 | ||
| EP15192851 | 2015-11-03 | ||
| EP16178010.1 | 2016-07-05 | ||
| EP16178010 | 2016-07-05 | ||
| PCT/EP2016/001791 WO2017076492A1 (en) | 2015-11-03 | 2016-10-27 | Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019500011A JP2019500011A (ja) | 2019-01-10 |
| JP2019500011A5 true JP2019500011A5 (enExample) | 2019-12-05 |
Family
ID=57544371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521237A Pending JP2019500011A (ja) | 2015-11-03 | 2016-10-27 | 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11235063B2 (enExample) |
| EP (2) | EP3909984A1 (enExample) |
| JP (1) | JP2019500011A (enExample) |
| CN (1) | CN108350078A (enExample) |
| AU (1) | AU2016349152A1 (enExample) |
| CA (1) | CA3003759A1 (enExample) |
| ES (1) | ES2875757T3 (enExample) |
| IL (1) | IL258980A (enExample) |
| WO (1) | WO2017076492A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3512882T (pt) * | 2016-09-14 | 2021-06-14 | Merck Patent Gmbh | Anticorpos anti-c-met e conjugados anticorpo-fármaco dos mesmos para inibição tumoral eficaz |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| RU2751720C2 (ru) * | 2017-05-30 | 2021-07-16 | Чонг Кун Данг Фармасьютикал Корп. | Новое анти-с-мет антитело и его применение |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| CN111499749B (zh) * | 2020-03-13 | 2021-11-09 | 浙江大学 | 一种西妥昔单抗突变体及应用 |
| WO2022104692A1 (en) * | 2020-11-20 | 2022-05-27 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Engineered antibody, antibody-drug conjugate, and use thereof |
| CN117480180A (zh) * | 2021-07-14 | 2024-01-30 | 江苏恒瑞医药股份有限公司 | 特异性结合hgfr和egfr的抗原结合分子及其医药用途 |
| CA3232216A1 (en) | 2021-10-18 | 2023-04-27 | Tavotek Biotherapeutics (Hong Kong) Limited | Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof |
| EP4429765A1 (en) * | 2021-11-10 | 2024-09-18 | Astrazeneca AB | Antibody molecules and conjugates |
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| WO2025025434A1 (zh) * | 2023-08-02 | 2025-02-06 | 百泰生物药业有限公司 | EGFR/c-Met双特异性抗体及其应用 |
| CN120000805A (zh) * | 2023-11-15 | 2025-05-16 | 四川科伦博泰生物医药股份有限公司 | 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途 |
| WO2025230410A1 (en) * | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2025230409A1 (en) * | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US273060A (en) | 1883-02-27 | Sheet-metal can | ||
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU2005267720B2 (en) * | 2004-08-05 | 2012-02-23 | Genentech, Inc. | Humanized anti-cmet antagonists |
| EP1957541A2 (en) * | 2005-11-21 | 2008-08-20 | Laboratoires Serono SA | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| ES2672769T3 (es) | 2007-08-29 | 2018-06-18 | Sanofi | Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| KR20110126748A (ko) * | 2009-04-07 | 2011-11-23 | 로슈 글리카트 아게 | 이중특이적 항-ｅｒｂｂ-1/항-ｃ-ｍｅｔ 항체 |
| KR20120057588A (ko) | 2009-05-28 | 2012-06-05 | 메르사나 테라퓨틱스, 인코포레이티드 | 가변 속도 방출 링커를 포함하는 폴리알 약물 접합체 |
| ES2993335T3 (en) * | 2010-03-10 | 2024-12-27 | Genmab As | Monoclonal antibodies against c-met |
| BR112013030472A2 (pt) * | 2011-06-30 | 2019-09-24 | Genentech Inc | formulação farmacêutica, artigo de fabricação e método |
| TW201326193A (zh) * | 2011-11-21 | 2013-07-01 | Genentech Inc | 抗－ｃ－ｍｅｔ抗體之純化 |
| RU2015100656A (ru) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения |
| AU2013347962B2 (en) * | 2012-11-21 | 2018-10-25 | Janssen Biotech, Inc. | Bispecific EGFR/c-Met antibodies |
| WO2014093379A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| EP2970435B1 (en) * | 2013-03-15 | 2020-08-12 | Eli Lilly and Company | Methods for producing fabs and bi-specific antibodies |
| KR102074421B1 (ko) * | 2013-03-29 | 2020-02-10 | 삼성전자주식회사 | 항 c-Met/항 EGFR 이중 특이 항체 |
| KR102089591B1 (ko) | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
-
2016
- 2016-10-27 EP EP21161478.9A patent/EP3909984A1/en not_active Withdrawn
- 2016-10-27 EP EP16810243.2A patent/EP3371223B1/en active Active
- 2016-10-27 US US15/773,555 patent/US11235063B2/en not_active Expired - Fee Related
- 2016-10-27 CA CA3003759A patent/CA3003759A1/en active Pending
- 2016-10-27 ES ES16810243T patent/ES2875757T3/es active Active
- 2016-10-27 CN CN201680064050.3A patent/CN108350078A/zh active Pending
- 2016-10-27 AU AU2016349152A patent/AU2016349152A1/en not_active Abandoned
- 2016-10-27 JP JP2018521237A patent/JP2019500011A/ja active Pending
- 2016-10-27 WO PCT/EP2016/001791 patent/WO2017076492A1/en not_active Ceased
-
2018
- 2018-04-26 IL IL258980A patent/IL258980A/en unknown
-
2021
- 2021-12-16 US US17/644,572 patent/US20220111064A1/en not_active Abandoned